BioCryst ends internal discovery programs, will close Alabama research facility

BioCryst is shutting down internal drug discovery and closing its Birmingham, AL research site, cutting 2026 opex guidance to $420–$440M while continuing work on navenibart and BCX17725.

Raccontata daendpoints.news